A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer.
Sherko KuemmelMario CamponeDelphine LoiratRafael Lopez LopezJ Thaddeus BeckMichelino De LaurentiisSeock-Ah ImSung-Bae KimAva KwongGuenther G StegerEsther Zamora AdelantadoFran Ois P DuhouxRichard GreilIrene KuterYen-Shen LuAriadna TibauMustafa ÖzgüroğluClaus-Jürgen ScholzChristian F SingerEstela VegaPauline WimbergerClaudio ZamagniXuan-Mai CouillebaultLiqiong FanNelson GuerreiroJennifer MatarazaJanna Sand-DejmekArlene ChanPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Despite successful target engagement and anticipated pharmacokinetic profile, lacnotuzumab + gem-carbo showed comparable antitumor activity to gem-carbo alone, with slightly poorer tolerability. However, the data presented in this article would be informative for future studies testing agents targeting the CSF1-CSF1 receptor pathway in TNBC.